American Society of Hematology

2017 Abstract Review Categories

100s - Red Cell Physiology and Disorders

Abstracts submitted to categories 101–114 will generally exclude studies of transplantation for red cell disorders and anemias, regardless of cause (see categories 721, 722, 723, 734, 735). Studies of erythroid differentiation and erythropoiesis should be submitted to categories 501–506.

101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron

Includes clinical and basic studies of normal or abnormal RBC membranes, proteins, and enzymes, and hematopoiesis of red blood cell precursors. This category also includes clinical and basic studies of anemia caused by systemic disease, red cell underproduction, and red cell overproduction. Includes anemia of the elderly, pathophysiology of anemia of chronic disease and inflammation (not related to perturbed iron metabolism), anemia of malaria, hemolytic anemia and paroxysmal nocturnal hemoglobinuria (except for PNH associated with marrow failure, which should be submitted to category 508), and other congenital anemias that do not lead to marrow failure. Includes physiology, pathophysiology, and management of all nutrition deficiencies excluding iron (see category 102). Molecular and genetic studies of erythroid-specific genes including, but not limited to alpha and beta hemoglobin are appropriate for this category. Studies of autoimmune hemolytic anemia (AIHA) are appropriate here, but consider also lymphocyte biology (203) or transfusion medicine (401) for some studies of immunodiagnosis, immunophenotyping, or immuno therapy in AIHA. Studies of congenital bone marrow failure syndromes including dyskeratosis congenita, Diamond-Blackfan anemia, and inherited aplastic anemia should be submitted to the category 508.

102. Regulation of Iron Metabolism

Includes physiology, pathophysiology, and management of the regulation of iron uptake, iron-dependent protein synthesis, and intrinsic disorders of heme synthesis. This category includes the genetics of iron overload syndromes, as well as the evaluation or treatment of hemochromatosis. Studies of the pathobiology, diagnosis, and treatment of iron deficiency are also appropriate.

112. Thalassemia and Globin Gene Regulation

Includes clinical and basic studies of alpha or beta thalassemia, persistence of hemoglobin F and investigation of control mechanisms of both normal and abnormal globin gene transcription.

113. Hemoglobinopathies, Excluding Thalassemia— Basic and Translational Science

Includes basic studies of sickle cell disease and sickle thalassemia, as well as new or known hemoglobinopathies. Also includes post-translational modulation of normal or abnormal hemoglobins.

114. Hemoglobinopathies, Excluding Thalassemia— Clinical

Includes clinical studies of sickle cell disease and sickle thalassemia, as well as new or known hemoglobinopathies.
back to top

200s - Leukocytes, Inflammation and Immunology

Abstracts submitted to categories 201–203 will generally exclude proliferation or differentiation of leukocytes and their precursors (see categories 501–506), leukemias (categories 601–618, 631, 632), post-transplantation lymphoproliferative disorders, GVHD/GVL activity and lymphocyte depletion (in vivo or in vitro) in stem cell processing (categories 701–711).

201. Granulocytes, Monocytes and Macrophages

Includes clinical and basic studies of normal or abnormal neutrophils or their precursors, monocytes, histiocytes, eosinophils, basophils or mast cells. Also includes some clinical, but primarily basic studies of all humoral and cell-surface molecules which modulate chemotaxis, phagocytic function or other inflammatory response to injury and infection. See also category 203 for interleukins, interferons and other lymphokines. Generally excludes growth factor therapy of neutropenias (see category 504) and transplantation or gene therapy of leukocyte disorders (see categories 701–732, 801). Studies of CGD, Gauchers disease or autoimmune neutropenias are appropriate here or in category 203 if the focus is on immunocompromised host infections.

203. Lymphocytes, Lymphocyte Activation and Immunodeficiency, including HIV and Other Infections

Includes clinical and basic studies of morphology, developmental biology and function of B and T cells, natural killer cells, dendritic cells, other immune active cells, antigen presentation or antibody production. Also includes interleukins, interferons, and related lymphokines which modulate immune cell function. Generally excludes paraproteinemias, dyscrasias, and amyloidosis (see categories 641–642 and 651–653). Studies of immune dysfunction intrinsic to hematologic malignancies may be better suited to categories 612–642, but include here studies of infectious complications of drug-induced myelotoxicity, including chemotherapy of hematologic malignancy or solid tumors.
back to top

300s - Hemostasis, Thrombosis and Vascular Wall Biology

301. Vascular Wall Biology, Endothelial Progenitor Cells, and Platelet Adhesion, Activation, and Biochemistry

Includes clinical and basic studies of angiogenesis, ontogeny, morphology, molecular biology or physiology of endothelium, endothelial progenitor cells, hemangioblasts or blood vessels, interaction with platelets or clotting factors, and primarily basic studies of platelet activation, including signal transduction and gene expression. Includes expression, regulation or characterization of platelet adhesion molecules, von Willebrand factor, or structural proteins and basic studies of biochemical or morphological determinants of platelet function. May include development of diagnostic platelet function tests. Generally excludes clinical thrombosis (see categories 331–332), unless the focus is on molecular or cellular processes. Some studies on vascular interaction with leukocytes or other inflammatory mediators may be better suited to category 201.

311. Disorders of Platelet Number or Function

Includes primarily clinical studies of thrombocytopenia, including autoimmune, alloimmune, infectious and drug-related causes as well as intrinsic and secondary disorders of platelet dysfunction. Includes ITP and TTP. Studies of megakaryopoiesis are better suited to category 501, and myeloproliferative disorders leading to abnormal platelet count are generally better suited to categories 634 and 635.

321. Blood Coagulation and Fibrinolytic Factors

Includes primarily basic studies of all clotting factors, fibrinolytic proteins, calcium, lipids, and related molecules which take part in blood coagulation or fibrinolysis as well as enzymes or proteases involved in their synthesis or degradation. Also includes gene expression and regulation. May include some in vitro clinical studies, such as diagnostic assay methods or development of laboratory tests for coagulopathy.

322. Disorders of Coagulation or Fibrinolysis

Includes primarily clinical studies of disorders of coagulation, von Willebrand’s disease or related bleeding diatheses. Excludes abnormal bleeding due to thrombocytopenia or platelet dysfunction. Studies of processing or handling of fractionated blood or plasma components used to treat hemophilia or coagulopathy may be better suited to category 401.

331. Pathophysiology of Thrombosis

Includes primarily clinical studies of thrombosis or hypercoagulability. May include some in vitro studies, such as development of laboratory tests for hypercoagulability.

332. Antithrombotic Therapy

Includes clinical studies of anticoagulants, antiplatelet agents, or thrombolytic agents. May include some in vitro studies, such as development of laboratory tests for monitoring anticoagulant therapy.
back to top

400s - Transfusion Medicine

401. Basic Science and Clinical Practice in Blood Transfusion

Includes clinical and basic studies of collection, handling, storage, or administration of blood or blood components. Also includes RBC or platelet antigen testing, prevention/detection/treatment of blood-borne infection, complications, and cost analysis. Generally excludes HIV infection, except screening or prevention. Also excludes stem cell processing for transplantation (see category 711).
back to top

500s - Hematopoiesis

Abstracts submitted to categories 501–506 should have as their primary focus cellular and molecular events involved in normal and reconstitutive hematopoiesis. Studies of similar mechanisms in the context of neoplastic transformation should be submitted to categories 601–603.

501. Hematopoietic Stem and Progenitor Biology

Cellular and molecular biology of all hematopoietic and non-hematopoietic stem cells, including their ability to differentiate to cell lineages belonging to various somatic tissues. Excludes preclinical or clinical transplantation-related uses of stem cell technology and processing (see category 711) and mesenchymal stem cells.

502. Hematopoiesis: Regulation of Gene Transcription, Cytokines, Signal Transduction, Apoptosis and Cell Cycle Regulation

Includes basic studies of genes, promoters or transcription factors which regulate hematopoietic cell proliferation or differentiation; hematopoietic growth factor activation, signaling intermediates and their targeting genes, including structural studies of the cytokines and cytokine receptors themselves; any cellular event that initiates, mediates, or promotes differentiation or phases of the cell cycle, including commitment to and execution of apoptosis. Also includes studies of clinical efficacy of growth factor analogues.

506. Hematopoiesis and Stem Cells: Microenvironment, Cell Adhesion and Stromal Stem Cells

Includes basic in vitro and in vivo animal studies of stromal cells, other cell populations, or matrix components that participate in modulation of hematopoiesis. Includes studies of mesenchymal cells and other microenvironmental cells in terms of their characterization and function in vitro and in vivo.

508. Bone Marrow Failure

Focuses on clinical and basic studies of hematopoietic cell underproduction including severe aplastic anemia, Fanconi anemia, Diamond-Blackfan anemia, dyskeratosis congenita, Shwachman Diamond syndrome, and bone marrow failure associated with paroxysmal nocturnal hemoglobinuria. All congenital and acquired bone marrow failure studies belong in this category.
back to top

600s - Hematologic Malignancy

Abstracts submitted to categories 601–653 will generally exclude studies of cellular differentiation, dedifferentiation, cell cycle and apoptosis, unless applicable to oncogenesis or malignancy therapy/recovery. Transplantation for neoplasia or premalignant conditions (any location) should be submitted to categories 721, 722, 723, 731, 732. Studies of quality of life or socioeconomic aspects should be submitted to category 901 or 902.

602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation

Includes functional studies of transcription factors and altered gene expression patterns involved in oncogenesis. Includes disordered epigenetic regulation and epigenomics. May include leukemias, lymphomas, lymphoproliferative disorders, and other malignant or premalignant conditions. Generally excludes transcription regulation in hematopoiesis, normal differentiation, and ontogeny (see categories 501–506).

603. Oncogenes and Tumor Suppressors

Includes primarily basic studies of specific oncogenes, tumor suppressors, or related loci in oncogenesis. Includes non-transcription factor oncogenes, knockout and deficient tumor suppressor gene models. May include leukemias, lymphomas, lymphoproliferative disorders, and other malignant or premalignant conditions. Generally excludes oncogenes and tumor suppressor gene expression in hematopoiesis, normal differentiation, and ontogeny (see categories 501–506).

604.Molecular Pharmacology, Drug Resistance– Myeloid diseases

Includes clinical and basic studies of interactions of therapeutic agents, potential agents, their receptors, binding sites and ligands related to myeloid diseases. Also includes pharmacokinetics, drug transport, metabolism and P-glycoprotein expression and function. Early studies of small molecule inhibitors and chemical biology may be more appropriate for category 802.

605. Molecular Pharmacology, Drug Resistance – Lymphoid and other diseases

Includes clinical and basic studies of interactions of therapeutic agents, potential agents, their receptors, binding sites and ligands related to lymphoid and other nonmyeloid diseases. Also includes pharmacokinetics, drug transport, metabolism and P-glycoprotein expression and function. Early studies of small molecule inhibitors and chemical biology may be more appropriate for category 802.

612. Acute Lymphoblastic Leukemia: Clinical Studies

Includes primarily clinical studies of epidemiology, complications, and follow-up, acute lymphocytic leukemias. May also include some studies of acute leukemia pathophysiology (systemic, cellular, or molecular) not covered in categories 601–605.

613. Acute Myeloid Leukemia: Clinical Studies

Includes primarily clinical studies of epidemiology, complications, and follow-up of acute myelogenous leukemias. May also include some studies of acute leukemia pathophysiology (systemic, cellular, or molecular) not covered in categories 601–605.

614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation

Includes clinical and animal model treatment using drug therapy, biological agents, immunotherapy, and vaccine development. For comparative trials of treatment regimens versus transplantation, see categories 731 and 732.

615. Acute Myeloid Leukemia: Commercially available Therapy, excluding Transplantation.

Includes clinical and animal model treatment using commercially available agents. For comparative trials of treatment regimens versus transplantation, see categories 731 and 732.

616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation.

Includes clinical and animal model treatment using novel drug therapy, biological agents, immunotherapy, and vaccine development. For comparative trials of treatment regimens versus transplantation, see categories 731 and 732.

617. Acute Myeloid Leukemia: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis.

Includes in vitro and clinical correlation studies of karyotype, biochemical, histochemical, or morphologic markers in acute myeloid leukemia. May also include minimal residual detection and preclinical or developmental studies of markers intended for eventual application to diagnosis and prognosis. This is the appropriate category for basic research in the molecular genetics of acute myeloid leukemia including cytogenetics, microarrays, and sequencing.

618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis

Includes in vitro and clinical correlation studies of karyotype, biochemical, histochemical, or morphologic markers in acute lymphoblastic leukemia. May also include minimal residual detection and preclinical or developmental studies of markers intended for eventual application to diagnosis and prognosis. This is the appropriate category for basic research in the molecular genetics of acute lymphoblastic leukemia including cytogenetics, microarrays, and sequencing.

621. Lymphoma—Genetic/epigenetic biology

Includes basic biologic and prognostic studies of Hodgkin and non-Hodgkin lymphoma involving genetic/epigenetic pathways, models or targets. Includes genome wide association studies or single nucleotide polymorphism studies, gene expression profiling, next generation sequencing, and biologic studies of the cell of origin. Also includes genetic/epigenetic studies in the context of therapy trials.

622. Lymphoma—Biology – non-genetic studies

Includes basic biologic and prognostic studies of Hodgkin and non-Hodgkin lymphoma involving the microenvironment, immune regulation, metabolic and other non-genetic pathways, models or targets. Includes target gene and proteomic analyses. Also includes non-genetic biologic prognostic studies in the context of therapy trials.

623. Mantle cell, follicular, and other indolent B Cell Lymphoma—Clinical studies

Includes clinical trials, retrospective/observational treatment studies, population-based studies of general treatment and phase IV studies of chemotherapy or novel therapies, biological agents, immunotherapy, and vaccine development for mantle cell and indolent B cell non-Hodgkin lymphoma, including follicular, Waldenstrom’s, marginal zone, mucosal associated lymphoid tissue, and hairy cell leukemia. Also includes clinical studies of risk factors, diagnosis, prognosis, biomarkers, imaging studies, epidemiology, complications, and follow-up of the above histologies. Studies with multiple histologies should be submitted to this category if mantle cell or indolent histologies predominate. Excludes transplantation. For comparative trials of treatment regimens versus transplantation, see categories 731 and 732. For studies of biologic prognostic factors in the context of therapy trials, see 621 or 622. For health services research related to lymphoma, see category 902. For outcomes and quality of life studies for lymphoma, see category 904.

624. Hodgkin lymphoma and T/NK cell lymphoma—Clinical studies

Includes clinical trials, retrospective/observational treatment studies, population-based studies of general treatment and phase IV studies of chemotherapy or novel therapies, biological agents, immunotherapy, and vaccine development for Hodgkin lymphoma and T cell lymphoma. Also includes natural killer cell lymphomas, mycosis fungoides, and Szeary syndrome. Includes clinical studies of risk factors, diagnosis, prognosis, biomarkers, imaging studies, epidemiology, complications, and follow-up of the above histologies. Studies with multiple histologies should be submitted to this category if Hodgkins or T/NK cell histologies predominate. Excludes transplantation. For comparative trials of treatment regimens versus transplantation, see categories 731 and 732. For studies of biologic prognostic factors in the context of therapy trials, see 621 or 622. For health services research related to lymphoma, see category 902. For outcomes and quality of life studies for lymphoma, see category 904.

625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents

Includes animal models using drugs, biologic agents, immunotherapy, and vaccine development.

626. Aggressive Lymphoma (diffuse large B cell and other aggressive B cell non-Hodgkin lymphomas)—Results from prospective clinical trials

Includes clinical trials of chemotherapy or novel therapies, biological agents, immunotherapy, and vaccine development for aggressive non-Hodgkin lymphoma, including diffuse large B cell and subtypes, Burkitt lymphoma, primary CNS lymphoma, and post-transplant lymphoproliferative disorder. Retrospective subset analyses from prospective clinical trials should be submitted to this category. Studies with multiple histologies should be submitted to this category if aggressive B cell histologies predominate. Excludes transplantation. For comparative trials of treatment regimens versus transplantation, see categories 731 and 732. For studies of biologic prognostic factors in the context of therapy trials, see 621 or 622.

627. Aggressive Lymphoma (diffuse large B cell and other aggressive B cell non-Hodgkin lymphomas)—Results from retrospective/observational studies

Includes clinical studies of risk factors, diagnosis, prognosis, biomarkers, imaging studies, epidemiology, complications, and follow-up of aggressive B cell lymphoma, including diffuse large B cell and subtypes, Burkitt lymphoma, primary CNS lymphoma, and post-transplant lymphoproliferative disorder. Studies with multiple histologies should be submitted to this category if aggressive B cell histologies predominate. Excludes transplantation. For studies that describe the outcomes of specific treatments for specific aggressive B cell lymphoma subtypes, see 626. For health services research related to lymphoma, see category 902. For outcomes and quality of life studies for lymphoma, see category 904.

631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy

Includes basic studies of any aspect of CML, including pre-clinical and animal models of drug therapy, biological agents, immunotherapy and vaccine development as well as pathophysiology at cellular or molecular levels.

632. Chronic Myeloid Leukemia: Therapy

Includes diagnosis, prognosis, therapy, epidemiology, complications, and follow-up. For comparative trials of treatment regimens versus transplantation, see categories 731 and 732.

634. Myeloproliferative Syndromes: Clinical

Includes all clinical studies of myeloproliferative syndromes, including myelofibrosis, essential thrombocythemia, polycythemia vera, mast cell disorders, and chronic eosinophilias: diagnosis, prognosis, epidemiology, complications, follow-up, and treatment. For comparative trials of treatment regimens versus transplantation, see categories 731 and 732. For studies on the molecular basis of myeloproliferative disorders, see category 635.

635. Myeloproliferative Syndromes: Basic Science

Includes all basic and preclinical studies of myeloproliferative syndromes, including the molecular basis of myelofibrosis, essential thrombocythemia, polycythemia vera, mast cell disorders, and chronic eosinophilias. For studies on the use of molecular diagnostic tools for diagnosis or prognosis, see category 634.

636. Myelodysplastic Syndromes – Basic and translational studies.

Includes all basic and preclinical studies of myelodysplastic syndromes, including RAEB and CMML, including the molecular basis of disease. For studies on the use of molecular diagnostic tools for diagnosis or prognosis, see category 637.

637. Myelodysplastic Syndromes – Clinical studies.

Includes all clinical studies of myelodysplastic syndromes, including RAEB and CMML: diagnosis, prognosis, epidemiology, complications, follow-up, vaccines and treatment. For studies on the molecular basis of myelodysplastic syndrome, see category 636. For comparative trials of treatment regimens versus transplantation, see categories 731 and 732.

641. CLL: Biology and Pathophysiology, excluding Therapy

Includes clinical and basic studies of diagnosis, prognosis (including CLL-specific markers), epidemiology, complications, and follow-up of chronic lymphocytic leukemia, hairy cell leukemia, paraproteinemias, dyscrasias, or amyloidosis. May also include some studies of pathophysiology (systemic, cellular or molecular) not covered in categories 601–605.

642. CLL: Therapy, excluding Transplantation

Includes clinical and animal model treatment using drug therapy, biological agents, immunotherapy, and vaccine development. For comparative trials of treatment regimens versus transplantation, see categories 731 and 732.

651. Myeloma: Biology and Pathophysiology, excluding Therapy

Includes studies of pathophysiology such as genomics (DNA, RNA, chromosomes), bone biology and the microenvironment (and how they may relate to disease progression) not covered in categories 601–605. Also includes clinical and basic studies of diagnosis, prognosis (including myeloma-specific markers), epidemiology, complications, and follow-up of myeloma.

652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy

Includes signal transduction studies, animal and pre-clinical models as well as preclinical studies of novel emerging therapies.

653. Myeloma: Therapy, excluding Transplantation

Includes treatment with drug therapy, biological agents, immunotherapy, and vaccine development. For comparative trials of treatment regimens versus transplantation, see categories 731 and 732.
back to top

700s - Transplantation

701. Experimental Transplantation: Basic Biology, Pre-Clinical Models

Includes preclinical in vivo animal models of transplantation to study basic biology, conditioning, engraftment, transplant complications, disease activity, immune function, GVHD and graft-versus-tumor effects.

703. Adoptive Immunotherapy

Includes pre-clinical in vitro and animal models of adoptive immunotherapy including T cells, regulatory cells, dendritic cells and other cell populations designed to treat malignancies or infections, and vaccine therapies.

711. Cell Collection and Processing

Includes pre-clinical scale-up and development, as well as clinical studies, of stem cell mobilization, collection (including leukapheresis, marrow harvest or cord blood procurement) of all stem cell or immune cell populations, purification of stem cells or specific immune cell populations, cryopreservation, removal or purging of tumor cells, red cells or T cells, expansion of stem cells or immune cell populations, or any other cell collection or processing topics not fitting in standard Transfusion Medicine category 401. Pre-clinical or clinical development of mesenchymal or other stromal cell populations is included in this category. Experimental studies of MSCs or stromal elements belong in category 506.

721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Transplant Toxicities

Includes clinical allogeneic transplantation studies encompassing engraftment, rejection, and chimerism; conditioning regimens including pharmacology/pharmacokinetics and regimen-related toxicities; transplantation-related supportive care including nutrition, treatment of acute toxicities such as nausea and vomiting, isolation, infection prophylaxis and detection and treatment of infectious complications of transplant, transfusion support, and growth-factor administration.

722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution

Includes clinical allogeneic transplantation studies of detection, prevention and management of acute and chronic GVHD, and immune reconstitution post-transplantation.

723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence

Includes clinical allogeneic or autologous transplantation studies of prevention, detection and management of relapse or minimal residual disease, via second transplants, donor lymphocyte infusions, other adoptive immunotherapy, biological agents or other approaches; studies of late effects of transplantation, including fertility, growth and development, psychological well-being, etc; post-transplantation lymphoproliferative syndrome detection and treatment; secondary malignancies, post-transplantation vaccination and long-term follow-up clinical care. Studies focused on quality of life or socioeconomic aspects should be submitted to category 901 or 902.

731. Clinical Autologous Transplantation: Results

Includes clinical autologous transplantation studies focusing on outcomes regarding disease activity and survival. Includes disease-specific outcomes, and comparative trials (for instance preparative regimens, chemotherapy versus transplant, etc.). Excludes studies on clinical care and on specific complications of transplant (see categories 721-723).

732. Clinical Allogeneic Transplantation: Results

Includes clinical allogeneic transplantation studies focusing on outcomes regarding disease activity and survival. Includes all cell sources whether PBSC, marrow, or cord blood, and whether family member or unrelated donor. Includes disease-specific outcomes, and comparative trials (for instance preparative regimens, ablative versus non-ablative, chemotherapy versus transplant, allogeneic versus autologous, PBSC versus marrow or cord blood, matched versus mismatched donors etc). Excludes studies on clinical care and on specific complications of transplant (see categories 721-723).
back to top

800s - Gene Therapy and Transfer, Chemical Biology and Experimental Therapeutics

801. Gene Therapy and Transfer

Includes basic studies of gene transfer techniques, including vector design, target cell physiology, and investigations of gene transfer efficiency. Also includes studies of marker gene insertion, vector-target cell interactions, and investigation of determinants of marker gene expression/regulation. Also includes preclinical and clinical applications of gene transfer and gene therapy in human disorders, in vivo animal models, and related settings.

802. Chemical Biology and Experimental Therapeutics

Includes the study and treatment of normal and malignant hematologic biology using small molecules and approaches rooted in organic chemistry. This category includes not only chemical probe discovery, but also the chemical optimization of molecules as therapeutic agents, and comparative analyses of pharmacologic agents in preclinical models. Abstracts on the science of proteomics, combinatorial chemistry, target identification and validation, screening methods, high-throughput assay development, hit-to-lead methodology, and lead optimization techniques are also appropriate for this category. Translational research performed on a single compound using specific disease model systems should be placed in disease-specific categories.
back to top

900s - Health Services and Outcomes Research

901. Health Services Research – Non-malignant conditions

Studies related to non-malignant conditions, including red cells, platelets, coagulation and other areas of hematology. Studies of non-malignant conditions in cancer populations, for example, thrombosis in a leukemia population, are also appropriate for this category. Includes studies relating to quality of care, comparative effectiveness, economics of hematologic services (cost-effectiveness analysis, cost-benefit/cost-utility analysis, resource utilization, epidemiology of cost and delivery of care), clinical pathways and practice guidelines, informatics (telemedicine, computer decision support), hematology education research (training programs, training and developing countries), and hematology in developing countries. Submissions on drugs or therapeutic trials are not appropriate for this section and will be better served in other categories. Quality improvement projects are also welcome in this abstract category. Abstracts should describe initiatives that aim to measure and/or improve the quality of healthcare delivery to individuals or populations. Work addressing any of the six IOM domains of quality are encouraged, namely: safety, effectiveness, patient-centeredness, timeliness, efficiency, and equity. Abstracts addressing value in healthcare are also encouraged.

902. Health Services Research – Malignant conditions

Studies of malignant conditions should be submitted to this category. Studies of non-malignant conditions in cancer populations should be submitted to category 901. Includes studies relating to quality of care, comparative effectiveness, economics of hematologic services (cost-effectiveness analysis, cost-benefit/cost-utility analysis, resource utilization, epidemiology of cost and delivery of care), clinical pathways and practice guidelines, informatics (telemedicine, computer decision support), hematology education research (training programs, training and developing countries), and hematology in developing countries. Submissions on drugs or therapeutic trials are not appropriate for this section and will be better served in other categories. Quality improvement projects are also welcome in this abstract category. Abstracts should describe initiatives that aim to measure and/or improve the quality of healthcare delivery to individuals or populations. Work addressing any of the six IOM domains of quality are encouraged, namely: safety, effectiveness, patient-centeredness, timeliness, efficiency, and equity. Abstracts addressing value in healthcare are also encouraged.

903. Outcomes Research – Non-malignant conditions

Studies related to non-malignant conditions, including red cells, platelets, coagulation and other areas of hematology should be submitted to this category. Studies of non-malignant conditions in cancer populations, for example, thrombosis in a leukemia population, are also appropriate for this category. Includes studies relating to outcomes research and quality of life (measurements, symptom management, and palliation). Submissions on drugs or therapeutic trials are not appropriate for this section and will be better served in other categories. Quality improvement projects are also welcome in this abstract category. Abstracts should describe initiatives that aim to measure and/or improve the quality of healthcare delivery to individuals or populations. Work addressing any of the six IOM domains of quality are encouraged, namely: safety, effectiveness, patient-centeredness, timeliness, efficiency, and equity. Abstracts addressing value in healthcare are also encouraged.

904. Outcomes Research – Malignant conditions

Studies of malignant conditions should be submitted to this category. Studies of non-malignant conditions in cancer populations should be submitted to category 901. Includes studies relating to outcomes research and quality of life (measurements, symptom management, and palliation). Submissions on drugs or therapeutic trials are not appropriate for this section and will be better served in other categories. Quality improvement projects are also welcome in this abstract category. Abstracts should describe initiatives that aim to measure and/or improve the quality of healthcare delivery to individuals or populations. Work addressing any of the six IOM domains of quality are encouraged, namely: safety, effectiveness, patient-centeredness, timeliness, efficiency, and equity. Abstracts addressing value in healthcare are also encouraged.
back to top